Prenetics Group (PRE)
NASDAQ:PRE
Want to see PRE full AI Analyst Report?
Top Page
Prenetics Group
(NASDAQ:PRE)
Select Model
Select Model
Rating:49Neutral
Price Target:
$14.50
▼(-18.68% Downside)
Action:Reiterated
Date:05/19/26
The score is held back primarily by continued losses and cash burn (financial performance) and a weak technical setup. The main offset is a strong earnings-call outlook with raised guidance, improving unit economics, and solid liquidity, but valuation remains constrained by negative earnings.
Positive Factors
Strong recurring revenue growth
Rapid, subscription-led top-line expansion and IM8’s large contribution imply a structurally recurring revenue base. High subscriber counts, rising servings and reported ARR-like metrics increase predictability of future cash flows and support scalable unit economics over the medium term.
Negative Factors
Negative operating and free cash flow
Multi-year negative operating and free cash flow means the business is consuming cash to fund growth. Even with strong revenue, sustained cash burn increases reliance on existing liquidity or future financing and raises execution risk if margin or subscriber trends slow.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong recurring revenue growth
Rapid, subscription-led top-line expansion and IM8’s large contribution imply a structurally recurring revenue base. High subscriber counts, rising servings and reported ARR-like metrics increase predictability of future cash flows and support scalable unit economics over the medium term.
Read all positive factors
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$262.69M
Dividend YieldN/A
Average Volume (3M)170.32K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth201.72%
EPS Growth-11.02%
CountryUS
Employees285
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-4.02
Shares Outstanding15,247,465
10 Day Avg. Volume145,161
30 Day Avg. Volume170,319
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap0.66
Enterprise Value/Revenue1.83
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$32.50Price Target Upside82.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.09
Revenue Forecast (FY)$191.89M
Prenetics Group Business Overview & Revenue Model
Company Description
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system th...
How the Company Makes Money
Prenetics makes money primarily by selling testing products and laboratory services. Key revenue streams have included: (1) Consumer and patient testing: revenue from at-home or consumer-initiated genetic tests and health screening tests, where cu...
Prenetics Group Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Sep 11, 2026
Earnings Call Sentiment Positive
The call presented a strongly positive operational narrative: very high revenue growth, significant improvement in gross margins, rapid cohort/LTV acceleration, healthy subscriber growth and consumption, raised guidance, and substantial cash resources after a Bitcoin sale. Management acknowledged near-term EBITDA losses driven by deliberate marketing investments to scale international quarterly subscriptions and noted preliminary accounting items pending close. Execution risks remain around channel diversification, potential reporting clarity, and delivering new product launches. On balance the positive growth, improving unit economics, and strong cohort metrics outweigh the near-term losses and execution items.Positive Updates
Strong Revenue Growth and IM8 Contribution
Total continuing operations revenue of $36.0M in Q1 2026, up ~333% year-over-year. IM8 contributed $33.8M (nearly 6x YoY) and was the primary driver of growth.
Negative Updates
Ongoing Operating Losses and Worsening Adjusted EBITDA
Loss from operations of $8.9M in Q1 2026 (vs. $6.0M in Q1 2025). Adjusted EBITDA loss widened to $5.6M from $4.5M year-over-year, reflecting elevated marketing investment during international quarterly subscription rollout.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth and IM8 Contribution
Total continuing operations revenue of $36.0M in Q1 2026, up ~333% year-over-year. IM8 contributed $33.8M (nearly 6x YoY) and was the primary driver of growth.
Read all positive updates
Company Guidance
Management raised full‑year 2026 IM8 revenue guidance to $190–$210 million (from $180–$200M) and guided Q2 total revenue of $46–$48 million with IM8 contributing $44–$46 million — roughly 33% sequential IM8 growth versus Q1 IM8 revenue of $33.8M; April IM8 monthly revenue was $14M (+18.6% vs March) and May is tracking to ~$15.5M (implying ~ $186M ARR). Q1 metrics include $36M total revenue, $23.3M gross profit, 64% IM8 gross margin, 8.8M servings (up 28% sequential), ~82k active subscribers, and 93% of IM8 revenue from subscriptions; guidance excludes three Q4 product launches (hydration, creatine, kids gummies) that management views as incremental upside.Prenetics Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M |
| Gross Profit | 48.79M | 15.40M | 8.83M | 3.62M | 3.60M |
| EBITDA | -32.19M | -51.57M | -47.90M | -218.04M | -209.16M |
| Net Income | -37.71M | -46.30M | -62.72M | -190.45M | -174.01M |
Balance Sheet | |||||
| Total Assets | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M |
| Total Debt | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M |
| Total Liabilities | 29.01M | 42.23M | 44.01M | 68.67M | 549.40M |
| Stockholders Equity | 174.60M | 170.39M | 206.36M | 237.06M | -400.81M |
Cash Flow | |||||
| Free Cash Flow | -22.02M | -29.94M | -14.68M | 8.17M | 2.00M |
| Operating Cash Flow | -21.81M | -28.87M | -13.76M | 14.51M | 13.42M |
| Investing Cash Flow | -35.79M | 38.54M | -82.95M | -46.14M | -22.02M |
| Financing Cash Flow | 37.54M | -3.34M | -4.70M | 143.32M | 29.32M |
Prenetics Group Technical Analysis
Negative
17.83
Price Trends
18.73
Negative
18.19
Negative
15.18
Negative
Market Momentum
-0.66
Positive
34.24
Neutral
32.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Negative. The current price of 17.83 is above the 20-day moving average (MA) of 17.15, below the 50-day MA of 18.73, and above the 200-day MA of 15.18, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 34.24 is Neutral, neither overbought nor oversold. The STOCH value of 32.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our securities may be delisted from NASDAQ as a result of our failure of meeting the NASDAQ continued listing requirements. Q4, 2023
2.
Our securities may be prohibited from being traded in the United States under the Holding Foreign Companies Accountable Act in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act, 2023, decreased the number of "non-inspection years" from three years to two years, and thus, reduced the time before our securities may be prohibited from trading or delisted. The delisting of our securities, or the threat of them being delisted, may materially and adversely affect the value of your investment. Q4, 2023
3.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations, and a majority of our directors and executive officers reside, outside of the United States. Q4, 2023
Prenetics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $631.28M | -6.09 | -55.89% | ― | -52.94% | 59.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $87.94M | -4.51 | -113.53% | ― | 20.55% | -4.63% | |
49 Neutral | $262.69M | -2.25 | -36.02% | ― | 201.72% | -11.02% | |
45 Neutral | $179.23M | -2.82 | -9.93% | ― | 4.69% | 84.60% | |
42 Neutral | $89.07M | -2.34 | -164.68% | ― | 69.52% | 58.15% | |
41 Neutral | $45.87M | -2.38 | 402.97% | ― | 17.42% | 42.75% |
* Healthcare Sector Average
PRE
Prenetics Group
14.54
7.24
99.18%
ACRS
Aclaris Therapeutics
4.40
3.05
225.93%
MDXH
MDxHealth
0.85
-1.31
-60.69%
STIM
Neuronetics
1.18
-3.11
-72.49%
XGN
Exagen
3.49
-2.47
-41.44%
BNR
Burning Rock Biotech
16.70
13.79
473.88%
Prenetics Group Corporate Events
Prenetics Lifts 2026 IM8 Revenue Outlook on Record Q1 Growth and Asset Divestiture
May 14, 2026
On May 14, 2026, Prenetics Global Limited reported preliminary unaudited results for the quarter ended March 31, 2026, with revenue surging to $36 million from $8.3 million a year earlier and gross profit rising to $23.3 million, despite a wider o...
Prenetics Names Veteran Finance Leader Brian Rosin CFO of Fast-Growing IM8 Brand
May 14, 2026
On May 14, 2026, Prenetics announced that industry veteran Brian J. Rosin has been appointed Chief Financial Officer of its IM8 subsidiary, providing dedicated finance leadership as the fast-growing premium nutrition brand continues its global rol...
Prenetics’ IM8 Secures Equity-Linked Multi-Year Supplement Partnership With Inter Miami CF
May 7, 2026
On May 7, 2026, Prenetics Global announced a multi-year deal making its IM8 brand the exclusive Official Health Supplements Partner of Inter Miami CF, the Major League Soccer club co-owned by David Beckham. The agreement embeds IM8 products such a...
Prenetics to Exit Bitcoin Holdings and Reinvest Up to $40 Million in Core IM8 Health Business
May 4, 2026
On May 1, 2026, Prenetics’ board approved the complete divestment of the company’s entire treasury position of about 510 Bitcoin, targeting completion of the sale by May 14, 2026 through institutional channels. Based on recent market p...
Prenetics Brings Giannis Antetokounmpo Onboard as IM8 Global Partner and Shareholder
Apr 2, 2026
On April 2, 2026, Prenetics announced a multi-year global partnership making NBA champion and two-time MVP Giannis Antetokounmpo a global partner of its IM8 brand and a shareholder in the company, marking him as the first NBA athlete to hold equit...
Prenetics Launches $40 Million Buyback as IM8 Growth, Liquidity Bolster Valuation Case
Mar 6, 2026
On March 6, 2026, Prenetics announced that its board authorized a 12‑month share repurchase program of up to $40 million in Class A ordinary shares, underscoring management’s belief that the stock is undervalued. The move follows about...
Prenetics Executives Boost Personal Share Purchases to $2.75 Million After Earnings
Mar 3, 2026
Prenetics Global Limited, a Nasdaq-listed consumer health sciences company and parent of the fast-growing IM8 premium nutrition brand, is expanding its position in the global wellness market with science-backed supplements sold in over 30 countrie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.